Atavistik Bio
Last verified 2026-05-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $120.0Mattributed |
|---|---|
| Latest round | series-d+, $120.0M, 2025-12-01attributed |
| Founded | 2020 |
| Headquarters | Cambridge USA |
| Industry | bio |
| Stage | series-b+ |
| Website | atavistik.bio |
Atavistik Bio develops precision allosteric small molecule therapeutics by identifying hidden binding pockets on drug targets. The company focuses on patients with oncology and rare disease needs where treatment options are limited. Its proprietary AMPS platform combines computational and experimental techniques to unlock cryptic allosteric sites.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-d+ | $120.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | atavistik.bio, read 2026-05-17 |
| Description | self-reported | atavistik.bio, read 2026-05-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.